Y Intercept Hong Kong Ltd Takes $589,000 Position in GeneDx Holdings Corp. $WGS

Y Intercept Hong Kong Ltd bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,380 shares of the company’s stock, valued at approximately $589,000.

Several other institutional investors also recently modified their holdings of the business. Chung Wu Investment Group LLC grew its holdings in shares of GeneDx by 8.2% in the second quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock valued at $305,000 after acquiring an additional 250 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock valued at $39,000 after acquiring an additional 264 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after acquiring an additional 453 shares in the last quarter. US Bancorp DE grew its holdings in shares of GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after acquiring an additional 548 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of GeneDx by 1.6% in the first quarter. Acadian Asset Management LLC now owns 36,182 shares of the company’s stock valued at $3,199,000 after acquiring an additional 567 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

WGS has been the subject of several recent analyst reports. BTIG Research upped their target price on GeneDx from $140.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wells Fargo & Company increased their price objective on GeneDx from $95.00 to $140.00 and gave the company an “equal weight” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a report on Wednesday, October 8th. Piper Sandler increased their price objective on GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Finally, Guggenheim reissued a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $129.22.

Insider Buying and Selling

In other GeneDx news, CFO Kevin Feeley sold 388 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $136.54, for a total transaction of $52,977.52. Following the sale, the chief financial officer owned 3,757 shares in the company, valued at $512,980.78. This represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jason Ryan sold 38,072 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director owned 103,284 shares in the company, valued at approximately $13,148,053.20. This represents a 26.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 556,375 shares of company stock worth $67,569,247. Insiders own 29.60% of the company’s stock.

GeneDx Trading Down 1.9%

NASDAQ:WGS opened at $136.87 on Thursday. The company has a market cap of $3.93 billion, a P/E ratio of 1,520.78 and a beta of 2.01. The stock’s fifty day moving average price is $125.01 and its two-hundred day moving average price is $99.86. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $146.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.21. The firm had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. GeneDx has set its FY 2025 guidance at EPS. As a group, analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.